ArticleCancer innovation2025
Bidirectional Causal Effect Between Gut Microbiota and Glioma Risk: A Systematic Review-Based Mendelian Randomization and Immune-Mediated Effect Analysis.
Article in Cancer innovation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Molecular mechanisms and clinical significance of the glioma metabolic-immune axis: a comprehensive review.Frontiers in immunology · 2026Review
- Bidirectional Causal Effect Between Gut Microbiota and Glioma Risk: A Systematic Review-Based Mendelian Randomization and Immune-Mediated Effect Analysis.Cancer innovation · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Glioma is the most common malignant tumor in the central nervous system, with unclear pathogenesis and poor treatment outcomes. Recent research reveals that the brain-gut axis-involving gut microbiota and immune activity-influences central nervous system tumors. Given the pivotal role of the brain-gut axis in glioma, our study aimed to elucidate the causal association between gut microbiota and glioma, and to identify potential immune-mediated effects and therapeutic targets. Methods: Based on publicly available genome-wide association study data, our research employed multi-subgroup, replicated, Bayesian weighted, and summary statistics-based two-sample Mendelian randomization (MR) studies, combined with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) systematic review strategy, to systematically evaluate the potential causal effects of gut microbiota on glioma and their immune-mediated traits. Results: The initial screening identified 53 gut microbiota and 58 plasma immune traits with potential causal associations with glioma. Through external data and systematic review from six studies, we ultimately confirmed five gut microbiota-plasma immune trait-glioma pathways. CD28 Conclusion: Our study, through MR analysis, revealed the causal relationship between gut microbiota and the susceptibility to glioma, and for the first time proposed the important role of circulating immune cells in this process, providing new potential biomarkers for the early diagnosis and treatment of glioma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.